Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK3389404
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
GSK3389404 is a liver-targeted antisense oligonucleotide developed for the treatment of chronic hepatitis B (CHB) virus infection. It is the N-acetyl galactosamine (GalNAc)-conjugated version of bepirovirsen (GSK3228836). The drug is designed to inhibit synthesis of hepatitis B surface antigen (HBsAg) and all other hepatitis B virus proteins by targeting a shared region present in all HBV mRNAs and pregenomic RNA. The GalNAc conjugation enhances delivery to hepatocytes. In clinical studies, GSK3389404 demonstrated dose-dependent reductions in HBsAg levels with an acceptable safety profile, though no effective dosing regimen was identified in Phase 2 trials.
- Other names
- IONIS-HBV-LRxISIS-GSK6-LRxISIS-GSK-6-LRxISIS-GSK 6-LRx
02
Targets
ASGPR (Asialoglycoprotein Receptor 1)HBV RNA (Hepatitis B virus RNA)L-HBsAg (Hepatitis B virus large envelope protein)
Beyond the preview
Go deeper on GSK3389404.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK3389404.